Overview
Employees
11-50
Total raised
$2.5M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 17, 2013 | Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million | That technology was spun into a company in 2008 with grants from the National Institutes of Health. Seattle-based BEAT is now led by Michael Kranda, a former chief operating officer of Immunex and CEO of Vaccinogen. Celladon Corp. and Belgi... |
| Apr 16, 2013 | BEATBio Closes $2.5M Seed Funding Round | BEATBio, a Seattle, Wash.-based biotechnology company focused on the development of a novel gene therapy for heart failure, closed a $2.5m seed funding. Backers included CET Capital Partners, with participation from the W Fund. The company ... |
| Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million | Damaged or weakened heart muscle that can’t pump enough blood to the rest of the body causes a host of problems that fall under the classification of heart failure. Researchers at the University of Washington have discovered a gene-based me... |
Reviews 0
FAQ about BEATBio Therapeutics
How much funding has BEATBio Therapeutics raised?
BEATBio Therapeutics has raised $2.5M in total across 1 funding round.
What has the press written about BEATBio Therapeutics?
Parsers VC has collected 4 articles mentioning BEATBio Therapeutics, among them “Gene therapy to restore muscle power to the heart nets UW spinoff $2.5 million” (Apr 17, 2013) and “BEATBio Closes $2.5M Seed Funding Round” (Apr 16, 2013).
Is BEATBio Therapeutics still active?
Yes, BEATBio Therapeutics is active; its latest activity on Parsers VC dates from Apr 17, 2013.